Dietary Supplement Climea Forte 30tabs.

Product Information

Estrogens may cause some degree of fluid retention. Women with conditions that might be influenced by this factor, such as a cardiac or renal impairment, warrant careful observation when estrogen-alone is prescribed. Hypocalcemia

After an average follow-up of 5.2 years, 28 women in the estrogen-alone group and 19 women in the placebo group were diagnosed with probable dementia. The relative risk of probable dementia for CE-alone versus placebo was 1.49 (95 percent CI, 0.83-2.66). The absolute risk of probable dementia for CE-alone versus placebo was 37 versus 25 cases per 10,000 women-years 8. In women with pre-existing hypertriglyceridemia, estrogen therapy may be associated with elevations of plasma triglycerides leading to pancreatitis. Consider discontinuation of treatment if pancreatitis occurs. Hepatic Impairment And/Or Past History Of Cholestatic Jaundice Inform postmenopausal women of possible less serious but common adverse reactions of estrogen-alone therapy such as headache, breast pain and tenderness, nausea and vomiting. Nonclinical Toxicology Carcinogenesis, Mutagenesis, Impairment Of Fertilityreceiving reports on adverse effects (the legal basis for processing is a legal obligation to which Aflofarm is subject – Article 6(1)(c) of the GDPR); All women should receive yearly breast examinations by a healthcare provider and perform monthly breast self-examinations. In addition, mammography examinations should be scheduled based on patient age, risk factors, and prior mammogram results. Ovarian Cancer

Climea Forte, a special supplement that affects the well-being and alleviate the discomfort of women, associated with menopause. The composition of the preparation is a double dose of soy isoflavones, which are classified as phytoestrogens - or plant counterparts of female hormones. Soy isoflavones are safe and have a mild effect on the endocrine women - without causing side effects. Due to the increased content of calcium and vitamin D3 Climea forte, also it allows you to maintain the proper structure and bone density. Enriched with the preparation that improves the appearance of the skin, and also relieves symptoms of fatigue and irritability associated with the menopause. Estradiol, estrone, and estriol are excreted in the urine along with glucuronide and sulfate conjugates. Adhesion Your personal data are processed by Aflofarm in accordance with Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation – “GDPR”). If your personal data are processed based on your consent, you may withdraw your consent to personal data processing at any time, whereas this will not affect lawfulness of prior processing. Treatment of moderate to severe symptoms ofvulvarand vaginal atrophyassociated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered.

Elimination Route

Moreover, estrogens (and progestogens) may elevate blood pressure and worsen the hypertension, thus compounding the risk. The Climara Forte transdermal delivery system continuously releases estradiol which is transported across intact skin leading to sustained circulating levels of estradiol during a 7-day treatment period. The systemic availability of estradiol after transdermal administration is about 20 times higher than that after oral administration. This difference is due to the absence of first pass metabolism when estradiol is given by the transdermal route. Subgroup analyses of women 50 to 59 years of age suggest no increased risk of stroke for those women receiving CE (0.625 mg)-alone versus those receiving placebo (18 versus 21 per 10,000 women-years). 1 Figure 1: Mean Serum 17β -Estradiol Concentrations versus Time Profile following Application of a 6.5 cm² Transdermal System and Application of a 12.5 cm² Climara Forte Transdermal System Start therapy with 0.025 mg per day applied to the skin once weekly. The dose should be adjusted as necessary to control symptoms. Clinical responses (relief of symptoms) at the lowest effective dose should be the guide for establishing administration of the Climara Forte transdermal system, especially in women with an intact uterus. Prevention Of Postmenopausal Osteoporosis

Calcium carbonate, soybean extract, bulking agent: cellulose, glazing agent: hydroxypropyl methylcellulose, hop cone extract, glazing agent: magnesium salts of fatty acids, cholecalciferol, ground linseed, bulking agent: sodium carboxymethylcellulose, alpha-crosslinked succinose tocopheryl, dye: titanium dioxide, glazing agent: hydroxypropylcellulose, pyridoxine hydrochloride, pteroylmonoglutamic acid, dyes: quinoline yellow and sunset yellow FCF, glazing agents: beeswax and carnauba wax. In the WHI estrogen plus progestin substudy (daily CE [0.625 mg] plus MPA [2.5 mg] versus placebo), there was a higher relative risk of nonfatal stroke and invasive breast cancer in women greater than 65 years of age. The Women’s Health Initiative Memory Study Table 1: Treatment-Emergent Adverse Reactions Reported at a Frequency of ≥ 5 Percent and More Frequent in Women Receiving Climara ForteTable 2 provides a summary of estradiol pharmacokinetic parameters determined during evaluation of the Climara Forte transdermal system.

Estrogen therapy should be used with caution in women with hypoparathyroidism as estrogen-induced hypocalcemia may occur. Exacerbation Of Endometriosis

Opis

Depression, migraine, paresthesia, dizziness, anxiety, irritability, mood swings, nervousness, insomnia, headache Miscellaneous The adhesion assessment was done visually on Days 2, 4, 5, 6, 7 of each week of transdermal system wear. A total of 1,654 adhesion observations were conducted for 333 transdermal systems of each size. Start therapy with 0.025 mg per day applied to the skin once weekly. Therapy should be started at the lowest effective dose and the shortest duration consistent with the treatment goals. Attempts to taper or discontinue the medication should be made at 3 to 6 month intervals. Treatment Of Moderate To Severe Symptoms Of Vulvar And Vaginal Atrophy Due To Menopause In the WHI estrogen-alone substudy, no overall effect on coronary heart disease (CHD) events (defined as nonfatal MI, silent MI, or CHD death) was reported in women receiving estrogen-alone compared to placebo 2.